HDAC10 Antibody

What is HDAC10 and how does it differ from other histone deacetylases?

HDAC10 is a 669-residue polypeptide with a distinctive bipartite modular structure consisting of an N-terminal Hda1p-related putative deacetylase domain and a C-terminal leucine-rich domain. Unlike other class II HDACs, HDAC10 functions primarily as a polyamine deacetylase (PDAC) that acts preferentially on N(8)-acetylspermidine, acetylcadaverine, and acetylputrescine, with attenuated catalytic activity toward N(1),N(8)-diacetylspermidine and minimal activity toward N(1)-acetylspermidine . While histone deacetylase activity has been observed in vitro, the physiological relevance of this protein/histone deacetylase activity remains unclear and could be very weak compared to its polyamine deacetylase function . Furthermore, HDAC10 is enriched in the cytoplasm, and this enrichment is not sensitive to leptomycin B, a specific inhibitor known to block the nuclear export of other class II HDAC members .

What are the key physiological functions of HDAC10?

HDAC10 participates in several crucial cellular processes based on current research. It may play a significant role in promoting late stages of autophagy, specifically autophagosome-lysosome fusion and/or lysosomal exocytosis in neuroblastoma cells . The enzyme is also implicated in DNA repair mechanisms, including homologous recombination and DNA mismatch repair, with evidence showing its involvement in MSH2 deacetylation . Recent studies have further revealed HDAC10's role in cancer progression, particularly in renal cell carcinoma (RCC), where it appears to promote tumor development by activating the Notch-1 pathway and downregulating PTEN expression levels . In transcriptional regulation, when tethered to a promoter, HDAC10 demonstrates the ability to repress transcription, and it selectively interacts with HDAC3 but not with HDAC4 or HDAC6 .

How is HDAC10 expression regulated in different tissues and disease states?

HDAC10 is widely expressed in adult human tissues and cultured mammalian cells, with varying levels of expression across different cell types . In pathological conditions such as clear cell renal cell carcinoma (ccRCC), HDAC10 shows significantly increased expression compared to normal tissues . Analysis of TCGA-KIRC dataset revealed that elevated HDAC10 expression significantly correlates with advanced pathological T-stage and metastasis in ccRCC patients . Immunohistochemistry studies have demonstrated that HDAC10 exhibits weak or negative staining in paraneoplastic tissues while showing robust and predominantly nuclear localization in ccRCC tissues, despite its generally cytoplasmic enrichment in normal cells . This altered expression and subcellular localization pattern may contribute to its role in cancer progression and could potentially serve as a prognostic marker.

What criteria should be considered when selecting an appropriate HDAC10 antibody for experimental use?

When selecting an HDAC10 antibody, researchers should consider several critical factors to ensure experimental success. First, evaluate the antibody's validated applications—different HDAC10 antibodies are optimized for specific techniques such as Western blot (WB), immunocytochemistry/immunofluorescence (ICC/IF), immunoprecipitation (IP), or flow cytometry . Second, confirm species reactivity and cross-reactivity—for instance, some antibodies like ab108934 react with human samples, while others like ab18971 react with mouse, rat, and human samples . Third, consider the antibody type and production method—options include rabbit polyclonal (ab18971) or rabbit recombinant monoclonal (ab108934) antibodies, each with different specificity profiles . Finally, review published validation data and citations to assess the antibody's performance in research similar to your planned experiments, paying particular attention to the specific epitope recognized and potential for non-specific binding.

How can I validate the specificity of an HDAC10 antibody?

Validating HDAC10 antibody specificity requires a multi-faceted approach. Begin with a Western blot analysis comparing lysates from cells with normal HDAC10 expression against those with HDAC10 knockdown (using shRNA or siRNA) to confirm the absence or reduction of the band at the predicted molecular weight (approximately 71 kDa) . Immunoprecipitation followed by mass spectrometry can provide definitive identification of the pulled-down protein as HDAC10 . For antibodies intended for immunocytochemistry, compare staining patterns in wildtype cells versus HDAC10-depleted cells, and perform co-localization studies with known HDAC10 interaction partners . Testing the antibody on transfected cell lysates expressing tagged HDAC10 provides another validation approach, as demonstrated with the 293T cells transfected with human HDAC10 expression vector containing myc-His-tag . Additionally, including appropriate positive controls (tissues/cells known to express HDAC10) and negative controls (primary antibody omission) in all experiments helps confirm specificity.

What are the optimal conditions for using HDAC10 antibodies in Western blotting?

For optimal Western blotting with HDAC10 antibodies, sample preparation and blotting conditions must be carefully controlled. Based on validated protocols, for purified ab108934, a dilution of 1/100 (2μg) is recommended when immunoprecipitating HDAC10 in whole cell lysates . For direct Western blotting, prepare protein samples in standard SDS-PAGE loading buffer, separate on 8-10% polyacrylamide gels (appropriate for the 71 kDa HDAC10 protein), and transfer to nitrocellulose membranes . For detection, a secondary antibody such as Goat Anti-Rabbit IgG H&L (HRP) at 1/20000 dilution (ab97051) works effectively with ab108934 . When using the polyclonal antibody ab18971, a concentration of 2.5 μg/mL has been validated for Western blot applications . Include positive controls such as Jurkat cell lysates, which express detectable levels of HDAC10 . To ensure specificity, incorporate HDAC10-depleted samples as negative controls and be aware that the predicted band size for HDAC10 is approximately 71 kDa .

How can HDAC10 antibodies be used effectively in immunofluorescence and immunocytochemistry?

For effective immunofluorescence and immunocytochemistry with HDAC10 antibodies, several methodological considerations are critical. When using purified ab108934 for immunocytochemistry analysis of Jurkat cells, optimal results are achieved at a 1:200 dilution (8.75 μg/ml) with cells fixed in 100% methanol . For immunofluorescence applications, consider counterstaining with markers of specific cellular compartments to evaluate HDAC10 localization—ab108934 has been successfully used with Alexa Fluor 594 Anti-alpha Tubulin antibody [DM1A] as a microtubule marker . For detection, secondary antibodies such as Goat Anti-Rabbit IgG H&L (Alexa Fluor 488) at 1:1000 (2 μg/ml) dilution provide strong signal with minimal background . HDAC10 typically shows cytoplasmic enrichment in normal cells, though nuclear localization has been observed in certain cancer tissues like ccRCC . Always include controls by omitting the primary antibody and using DAPI as a nuclear counterstain to distinguish genuine HDAC10 signals from background fluorescence.

What protocol should be followed for flow cytometry analysis using HDAC10 antibodies?

For flow cytometry analysis using HDAC10 antibodies, a detailed intracellular staining protocol is necessary as HDAC10 is primarily an intracellular protein. Begin with cell preparation by harvesting approximately 1×10^6 cells per sample, washing with PBS, and fixing with 4% paraformaldehyde for 10-15 minutes at room temperature . After fixation, permeabilize cells with 90% methanol, which has been validated for successful intracellular staining with ab108934 . For HDAC10 staining, use purified ab108934 at a 1/200 dilution (10 μg/ml) and incubate for 30-60 minutes at room temperature or 4°C overnight . Following primary antibody incubation, wash cells thoroughly and apply a fluorophore-conjugated secondary antibody such as Goat anti-rabbit IgG (Alexa Fluor 488) at a 1/2000 dilution . Include appropriate controls in your experimental design: an isotype control (rabbit monoclonal IgG) to assess non-specific binding and an unlabeled control (cells without primary and secondary antibody incubation) to establish baseline fluorescence . This methodology allows for quantitative analysis of HDAC10 expression levels across different cell populations or experimental conditions.

How can I use HDAC10 antibodies for immunoprecipitation studies?

For successful immunoprecipitation (IP) of HDAC10, follow this validated protocol: prepare whole cell lysates in a buffer containing 20 mM Tris-HCl pH 8.0, 10% glycerol, 5 mM MgCl₂, and protease inhibitors . For IP using ab108934, employ a 1/100 dilution (2μg) with anti-Flag M2 agarose beads when using tagged constructs . Incubate lysates with the antibody-bead complex overnight at 4°C with gentle rotation to ensure efficient binding. After incubation, wash the immunocomplexes four times with buffer containing 0.15 M KCl to remove non-specific interactions . Elute bound proteins using either specific Flag peptide competition or 0.1 M glycine-HCl pH 2.5 . For co-immunoprecipitation studies investigating HDAC10 interactions with other proteins (such as HDAC3), co-transfect cells with tagged HDAC10 (Flag-tagged) and the potential interaction partner (HA-tagged), then perform IP as described . Following elution, analyze the immunoprecipitated proteins by SDS-PAGE and Western blotting with appropriate antibodies to detect both HDAC10 and its interaction partners .

What are common issues when working with HDAC10 antibodies and how can they be resolved?

When working with HDAC10 antibodies, researchers commonly encounter several challenges that can be systematically addressed. For weak or absent signals in Western blots, consider: increasing antibody concentration (validated dilutions are 1/100 for ab108934 and 2.5 μg/mL for ab18971), optimizing protein extraction methods to prevent HDAC10 degradation, or using fresh lysates as HDAC10 may be sensitive to freeze-thaw cycles . High background in immunocytochemistry can be reduced by: increasing blocking time with 5% BSA or serum, optimizing antibody dilution (1:200 or 8.75 μg/ml for ab108934 has been validated), or using alternative fixation methods (100% methanol has shown good results) . For non-specific bands in Western blotting, consider using cell lysates with HDAC10 knockdown as negative controls and optimize washing steps to reduce non-specific binding . Poor immunoprecipitation efficiency can be improved by adjusting lysis buffer composition (20 mM Tris-HCl pH 8.0, 10% glycerol, 5 mM MgCl₂ with protease inhibitors has been effective) or increasing incubation time with antibody-bead complex .

How can I determine if my HDAC10 antibody is still functional after storage?

To assess whether your HDAC10 antibody remains functional after storage, implement a systematic quality control approach. First, perform a Western blot using a positive control sample known to express HDAC10, such as Jurkat or HeLa cell lysates, comparing the current results with previous data or expected band intensity at 71 kDa . Include a loading control antibody in parallel to normalize for protein loading variations. For immunofluorescence applications, test the antibody on fixed cells that reliably express HDAC10 (e.g., Jurkat cells) and evaluate both signal intensity and the expected subcellular localization pattern (cytoplasmic enrichment in most normal cells) . If signal intensity appears diminished compared to previous experiments, try using a higher antibody concentration or shorter dilution. For quantitative applications like flow cytometry, compare the mean fluorescence intensity obtained with the potentially compromised antibody against historical values using the same experimental conditions and cell types . Consider aliquoting antibodies upon receipt to minimize freeze-thaw cycles, storing at recommended temperatures (typically -20°C for long-term storage), and adding preservatives like sodium azide (0.02%) to prevent microbial contamination in working dilutions.

What controls should be included when using HDAC10 antibodies in experiments?

Rigorous experimental design with appropriate controls is essential when working with HDAC10 antibodies. Positive controls should include: cell lines with confirmed HDAC10 expression (HeLa, Jurkat, or 293T cells transfected with human HDAC10 expression vector) ; recombinant HDAC10 protein when available; and tissues known to express HDAC10 (widely expressed in adult human tissues) . Negative controls should incorporate: cells with HDAC10 knockdown using validated shRNA or siRNA approaches; primary antibody omission in immunostaining protocols; and isotype controls (rabbit monoclonal IgG for ab108934) to assess non-specific binding in flow cytometry . For immunoprecipitation experiments, include a mock IP condition without specific antibody to identify non-specific binding to beads or matrix . When studying HDAC10 function, include a trichostatin A treatment group, as HDAC10's histone deacetylase activity is sensitive to this specific inhibitor . For Western blots, incorporate molecular weight markers to confirm the expected band size of approximately 71 kDa . These controls collectively ensure experimental validity and facilitate accurate interpretation of results obtained with HDAC10 antibodies.

How does HDAC10 contribute to cancer progression and what methodologies can be used to study this?

HDAC10 contributes to cancer progression through multiple mechanisms that can be investigated using specific methodological approaches. In clear cell renal cell carcinoma (ccRCC), elevated HDAC10 expression is associated with advanced pathological T-stage and metastasis, suggesting a role in tumor progression . To study HDAC10's oncogenic functions, researchers can employ HDAC10 knockdown using shRNA in cancer cell lines (as demonstrated in A498 and Caki-2 RCC cells) followed by functional assays including MTT proliferation assays, colony formation assays, and Transwell migration assays . Flow cytometry analysis after HDAC10 knockdown reveals significant increases in apoptosis and cell cycle arrest in G0/G1 phase, indicating HDAC10's anti-apoptotic and cell cycle regulatory functions . At the molecular level, HDAC10 appears to promote RCC development by activating the Notch-1 pathway and downregulating PTEN expression, which can be assessed through Western blotting and qRT-PCR analysis of these pathway components after HDAC10 manipulation . In neuroblastoma, HDAC10 may promote late stages of autophagy, suggesting another mechanism of cancer promotion that can be studied through autophagosome-lysosome fusion assays and lysosomal exocytosis measurements .

What is known about HDAC10's role in DNA repair mechanisms and how can this be experimentally investigated?

HDAC10 plays significant roles in DNA repair mechanisms, particularly in homologous recombination and DNA mismatch repair, which can be investigated through specialized experimental approaches . For studying HDAC10's involvement in homologous recombination, researchers can utilize reporter assays with DR-GFP plasmids that measure homology-directed repair efficiency in cells with modulated HDAC10 expression . To investigate HDAC10's role in DNA mismatch repair, researchers should examine its interaction with MSH2, as HDAC10 has been shown to be involved in MSH2 deacetylation . This can be studied through co-immunoprecipitation experiments using HDAC10 antibodies followed by Western blotting for MSH2, or through proximity ligation assays to visualize HDAC10-MSH2 interactions in situ. The functional consequences of these interactions can be assessed using microsatellite instability assays or mutation frequency assays in cells with HDAC10 knockdown or overexpression. Additionally, researchers can measure the acetylation status of MSH2 using acetylation-specific antibodies after modulating HDAC10 expression to directly link HDAC10's deacetylase activity to MSH2 function in DNA repair . These approaches collectively provide mechanistic insights into how HDAC10 influences genomic stability through regulation of DNA repair pathways.

What experimental approaches can be used to study HDAC10's polyamine deacetylase activity versus its histone deacetylase activity?

Distinguishing between HDAC10's polyamine deacetylase (PDAC) activity and its histone deacetylase activity requires specific experimental designs targeting each function. To study HDAC10's predominant PDAC activity, which acts preferentially on N(8)-acetylspermidine, acetylcadaverine, and acetylputrescine, researchers can employ in vitro enzymatic assays using purified recombinant HDAC10 and synthetic acetylated polyamine substrates . The deacetylation reaction can be monitored through HPLC analysis, mass spectrometry, or colorimetric assays measuring released acetate. For cellular studies, researchers can modulate HDAC10 expression (overexpression or knockdown) and measure changes in cellular polyamine acetylation profiles using targeted metabolomics approaches. In contrast, HDAC10's histone deacetylase activity, which has been observed in vitro but may have limited physiological relevance, can be assessed through in vitro deacetylation assays using purified histones or histone peptides as substrates . In cellular contexts, changes in specific histone acetylation marks can be measured by Western blotting with acetylation-specific antibodies after HDAC10 modulation. To determine the relative importance of these activities, researchers can perform comparative analysis of enzyme kinetics (Km and Vmax values) with different substrates. Additionally, the sensitivity of both activities to trichostatin A, a specific inhibitor for class I and II histone deacetylases, provides another approach to characterize HDAC10's dual enzymatic functions .

How can HDAC10's potential as a therapeutic target be evaluated in disease models?

Evaluating HDAC10's potential as a therapeutic target in disease models requires a multi-faceted approach addressing both efficacy and specificity. For cancer models, researchers should first establish the correlation between HDAC10 expression and clinical outcomes using tissue microarrays and patient data, as demonstrated in ccRCC where elevated HDAC10 expression associates with unfavorable prognosis . In cellular models, systematic HDAC10 knockdown using shRNA or CRISPR-Cas9 followed by comprehensive phenotypic analysis (proliferation, migration, apoptosis, and cell cycle assays) provides insights into the therapeutic potential of HDAC10 inhibition . The table below summarizes key cellular effects observed after HDAC10 knockdown in ccRCC cells:

For in vivo evaluation, xenograft models using cells with HDAC10 knockdown or treatment with selective HDAC10 inhibitors can assess tumor growth inhibition and survival benefits . Mechanistic studies should investigate the impact of HDAC10 inhibition on key signaling pathways, such as Notch-1 activation and PTEN expression in RCC, or autophagy regulation in neuroblastoma cells . Finally, toxicity studies in appropriate animal models are essential to evaluate potential off-target effects and establish a therapeutic window for HDAC10-targeted interventions.

How can HDAC10 antibodies be utilized in high-throughput screening assays?

HDAC10 antibodies can be effectively incorporated into high-throughput screening platforms with appropriate methodological adaptations. For cell-based screening of HDAC10 modulators, researchers can develop ELISA-based detection systems using HDAC10 antibodies in 96- or 384-well formats . This approach begins with cells treated with compound libraries, followed by fixation, permeabilization, and detection of HDAC10 expression or post-translational modifications using validated antibodies like ab108934 at optimized dilutions . For activity-based screens, antibodies that specifically recognize acetylated substrates of HDAC10 (such as acetylated polyamines or specific histone residues) can be employed to measure deacetylase activity after compound treatment. Flow cytometry-based high-throughput approaches are also feasible, as HDAC10 antibodies have been validated for intracellular staining in flow cytometry applications . For this method, treat cells in multi-well plates, process for intracellular staining with HDAC10 antibodies (1/200 dilution or 10 μg/ml for ab108934), and analyze using automated flow cytometry systems . Additionally, high-content imaging platforms can utilize fluorescently-tagged secondary antibodies to detect HDAC10 subcellular localization changes in response to treatments, providing spatial information not available from other screening approaches.

What are the considerations for using HDAC10 antibodies in chromatin immunoprecipitation (ChIP) experiments?

While HDAC10 is primarily known for its cytoplasmic localization and polyamine deacetylase activity, its potential nuclear functions and histone deacetylase activity observed in vitro make chromatin immunoprecipitation (ChIP) experiments relevant but challenging . When designing ChIP experiments with HDAC10 antibodies, several considerations are crucial. First, antibody selection should prioritize high specificity and affinity for the native conformation of HDAC10, as the nuclear pool of HDAC10 may be limited . Second, crosslinking conditions may need optimization—standard 1% formaldehyde crosslinking for 10 minutes may be sufficient for HDAC10 bound directly to DNA, but longer crosslinking times or alternative crosslinkers like DSG (disuccinimidyl glutarate) may be necessary to capture HDAC10 interacting with chromatin through protein complexes . Third, cell type selection is critical—choose cells where HDAC10 has been shown to have nuclear localization, such as certain cancer cell types where abnormal nuclear accumulation has been observed . Fourth, include appropriate positive controls (regions known to be regulated by histone deacetylases) and negative controls (IgG ChIP, gene desert regions) to establish signal specificity. Finally, consider ChIP-seq approaches to identify genome-wide binding patterns of HDAC10, which might reveal unexpected targeting mechanisms beyond its known role in transcriptional repression when tethered to promoters .

How can quantitative proteomic approaches be combined with HDAC10 antibodies to identify novel substrates or interacting partners?

Combining quantitative proteomics with HDAC10 antibodies offers powerful approaches to discover novel substrates and interaction partners. Immunoprecipitation coupled with mass spectrometry (IP-MS) represents a foundational method—purify HDAC10 protein complexes using validated antibodies like ab108934 at 1/100 dilution (2μg), followed by in-solution digestion and liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis . For more specific identification of HDAC10 substrates, researchers can employ acetylome profiling by comparing the global acetylation patterns between normal and HDAC10-depleted cells through stable isotope labeling with amino acids in cell culture (SILAC) followed by acetylated peptide enrichment using anti-acetyl-lysine antibodies and MS analysis. Proximity-dependent biotin identification (BioID) offers another approach—fuse HDAC10 to a promiscuous biotin ligase, allow biotinylation of proximal proteins, and purify these using streptavidin beads followed by MS identification. For validating direct interactions, researchers can use crosslinking immunoprecipitation followed by MS (CLIP-MS), which stabilizes transient interactions through chemical crosslinking before HDAC10 immunoprecipitation. These methods can reveal not only protein interactors but also potential non-histone substrates for HDAC10's deacetylase activity, expanding our understanding beyond its established role in polyamine deacetylation and providing insights into its diverse cellular functions.

How can I design experiments to study the functional consequences of HDAC10 in cancer cell models?

To comprehensively investigate HDAC10's functional impact in cancer models, implement a multi-level experimental design. Begin with expression modulation through stable HDAC10 knockdown using validated shRNA constructs or CRISPR-Cas9 genome editing in appropriate cancer cell lines, such as A498 and Caki-2 for renal cell carcinoma studies . Confirm knockdown efficiency using both qRT-PCR and Western blot analysis to ensure both transcript and protein levels are reduced . Follow with functional phenotyping through a battery of assays: MTT or MTS assays to measure proliferation over 24-96 hours; colony formation assays to assess long-term growth potential; Transwell migration assays to quantify cell motility; and flow cytometry for cell cycle distribution (using propidium iodide staining) and apoptosis (using Annexin V/PI double staining) . For mechanistic insights, analyze pathway alterations focusing on the Notch-1 signaling pathway and PTEN expression levels, which have been implicated in HDAC10-mediated cancer progression . Additionally, assess autophagy markers if studying neuroblastoma models, as HDAC10 influences late-stage autophagy in these cells . For in vivo relevance, establish xenograft models using HDAC10-depleted cells and monitor tumor growth, invasion, and metastasis. Finally, analyze patient-derived samples for correlations between HDAC10 expression and clinical features, including tumor stage, metastasis status, and patient survival .

What approaches can be used to study HDAC10's role in autophagy regulation?

Investigating HDAC10's role in autophagy regulation, particularly in neuroblastoma cells where it may promote late stages of autophagy, requires specialized methodological approaches . Begin with HDAC10 expression modulation using shRNA knockdown or overexpression systems, comparing autophagy markers and flux in normal versus HDAC10-altered cells. For assessing autophagosome formation and accumulation, measure LC3-I to LC3-II conversion through Western blotting and visualize LC3 puncta formation using immunofluorescence with anti-LC3 antibodies in fixed cells or GFP-LC3 in live cells . To specifically examine HDAC10's proposed role in autophagosome-lysosome fusion, implement colocalization studies of LC3 (autophagosome marker) with LAMP1 or LAMP2 (lysosomal markers) using confocal microscopy, calculating Pearson's correlation coefficients to quantify fusion events. For lysosomal exocytosis assessment, measure the release of lysosomal enzymes such as β-hexosaminidase into culture medium or analyze the plasma membrane translocation of lysosomal proteins like LAMP1 through cell surface biotinylation or immunofluorescence without permeabilization. Additionally, employ lysosomal function assays including LysoTracker staining for acidification, DQ-BSA degradation for proteolytic activity, and Magic Red cathepsin assays for specific protease activities. Compare these parameters between control and HDAC10-modulated cells, both under basal conditions and after autophagy induction with rapamycin or starvation, to comprehensively characterize HDAC10's specific contributions to autophagy regulation.